GLP-1 receptor agonists increase suicidal ideation or suicide.
- Current status
- Not supportedEvidence weakening · Psychiatric
- Why
- Pharmacovigilance reports prompted regulatory review. Two large cohorts (US EHR; Swedish/Danish registers with SGLT2i active comparator) found no increase in suicidal ideation or suicide death; the Nordic upper confidence limit excludes more than 0.16 extra deaths per 1,000 person-years.
- What would change it
- A signal in randomized psychiatric adverse-event data or in people with pre-existing psychiatric illness.
- Linked studies
- 2 · 2 contradicts
- Last updated
- Sep 13, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Contradicts (2)
- Association of semaglutide with risk of suicidal ideation in a real-world cohortRetrospective cohort · 2024 · Study tier 3 · Different population · Null
TriNetX: HR 0.27 for incident suicidal ideation vs non-GLP-1 anti-obesity drugs.
- GLP-1 Receptor Agonist Use and Risk of Suicide DeathRetrospective cohort · 2024 · Study tier 3 · Different population · Null
Nordic registers: suicide death HR 1.25 (0.83-1.88); self-harm composite HR 0.83.
02History
How this assessment has changed
- Not supportedSep 13, 2026 · Evidence weakening
initial curated status